Schmitt, S., Ho, A. D., & Goldschmidt, H. (2010). The oral histone deacetylase inhibitor LBH589 is a potential and promising therapeutic agent in multiple myeloma after at least two lines of chemotherapy including bortezomib or lenalidomide. Onkologie, 33(4), . https://doi.org/10.1159/000286447
Chicago-Zitierstil (17. Ausg.)Schmitt, Stefan, Anthony Dick Ho, und Hartmut Goldschmidt. "The Oral Histone Deacetylase Inhibitor LBH589 Is a Potential and Promising Therapeutic Agent in Multiple Myeloma After at Least Two Lines of Chemotherapy Including Bortezomib or Lenalidomide." Onkologie 33, no. 4 (2010). https://doi.org/10.1159/000286447.
MLA-Zitierstil (9. Ausg.)Schmitt, Stefan, et al. "The Oral Histone Deacetylase Inhibitor LBH589 Is a Potential and Promising Therapeutic Agent in Multiple Myeloma After at Least Two Lines of Chemotherapy Including Bortezomib or Lenalidomide." Onkologie, vol. 33, no. 4, 2010, https://doi.org/10.1159/000286447.